Breaking News
October 23, 2018 - WHO says Zika risk low in Pacific ahead of Meghan visit
October 23, 2018 - A deeper look at ‘Reflecting Frankenstein’
October 23, 2018 - Breastfeeding can have protective affect against high blood pressure in women, confirms study
October 23, 2018 - Epigenetic modifications may contribute to Alzheimer’s Disease
October 23, 2018 - Volunteering for peer counseling programs benefits people with lupus
October 23, 2018 - Cancer treatment may undergo a paradigm shift to immunotherapy soon
October 23, 2018 - Study uncovers new mechanism of action in a first-line drug for diabetes
October 23, 2018 - New type of molecule shows early promise against treatment-resistant prostate cancer
October 23, 2018 - Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients
October 23, 2018 - Scientists grow functioning human neural networks in 3D from stem cells
October 23, 2018 - Using mushrooms as a prebiotic may help improve glucose regulation
October 23, 2018 - New ENT clinic treats children in Zimbabwe
October 23, 2018 - CUIMC Celebrates 2018-2019, Issue 2
October 23, 2018 - Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer
October 23, 2018 - Polyganics begins first-in-human clinical trial of LIQOSEAL for reducing CSF leakage
October 23, 2018 - Gut bacterial community of healthy adults recovers after short-term exposure to broad-spectrum antibiotics
October 23, 2018 - Lowering systolic blood pressure does not damage the kidneys, shows study
October 23, 2018 - Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
October 23, 2018 - Cardiovascular admissions more common among most deprived
October 23, 2018 - Targeted drug and hormone therapy combination extends breast cancer survival
October 23, 2018 - Map of human liver cells reveals molecular make-up of individual cells
October 23, 2018 - Drugs approved for breast cancer treatment are effective and well tolerated in men
October 23, 2018 - EKF introduces new hand-held lactate analyzer for rapid sports performance monitoring
October 23, 2018 - Researchers identify common genetic connection in lung conditions
October 23, 2018 - Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC
October 23, 2018 - Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer
October 23, 2018 - New discovery may lead to better treatment options for pancreatic cancer patients
October 23, 2018 - FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
October 23, 2018 - Researchers identify immune culprits linked to inflammation and bone loss in gum disease
October 23, 2018 - Despite lower risk factors, black men have higher rates of recidivism
October 23, 2018 - Study finds why pregnant women in mainland China, Hong Kong and Taiwan prefer cesarean delivery
October 23, 2018 - AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis
October 23, 2018 - NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors
October 23, 2018 - Scientists use electron microscope to study chemical transformation in catalytic cross-coupling reaction
October 23, 2018 - Research offers new hope to men who received childhood cancer treatment
October 23, 2018 - New medical navigation system receives international innovation award
October 23, 2018 - Adverse Childhood Experiences Tied to Burnout in BSN Students
October 23, 2018 - High levels of oral disease among elite athletes affecting performance
October 23, 2018 - Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
October 23, 2018 - LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
October 23, 2018 - Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
October 23, 2018 - Organic food may protect against cancers finds study
October 23, 2018 - Interweaving anxiety disorder associated with stuttering remains unrecognized
October 23, 2018 - Cannabis oil shown to significantly improve Crohn’s disease symptoms
October 23, 2018 - Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
October 23, 2018 - Common antibodies associated with myocardial infarction
October 23, 2018 - Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
October 23, 2018 - Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
October 23, 2018 - Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
October 23, 2018 - Can virtual reality help people become more compassionate?
October 23, 2018 - Screen time eclipsed outdoor time for most students, shows study
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
October 23, 2018 - Cancer stem cells use ‘normal’ genes in abnormal ways
October 23, 2018 - Bad Blood: A conversation with investigative reporter John Carreyrou | News Center
October 23, 2018 - As U.S. fertility rates collapse, finger-pointing and blame follow
October 23, 2018 - Researchers develop promising targeted strategy to treat chemo-resistant blood cancer
October 23, 2018 - Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus
October 23, 2018 - Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
October 23, 2018 - 11th World Stroke Congress examines high stroke impact in low- and middle-income countries
October 22, 2018 - Breast cancer survival could be extended with two new drug combinations
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
Optimal Biomarker Frequency for Biosensors

Optimal Biomarker Frequency for Biosensors

image_pdfDownload PDFimage_print

An interview with Chi-En Lin Metrohm Young Chemist of the Year, conducted by Alina Shrourou and James Ives

Please give a brief overview of how we currently diagnose and manage complex diseases and their comorbidities. Why is there a pressing need for advancements in this field?

Optical methods, such as ELISA, are considered state of the art. These analyze samples with fluorescent or other signaling labels and yield accurate detection, but the preparation is expensive and complicated, they require trained personnel and hi-tech instruments.

In order to achieve point of care testing for personalized medicine, bio assays need to be able to detect biomarkers at a much faster, cheaper rate without sacrificing accuracy.

Chi-En Lin 2018 Metrohm USA Young Chemist Winner.

Chi-En Lin won Metrohm’s Young Chemist of the Year award for his research into optimal biomarker frequencies, not just the novelty of the research but how it can be applied. Determining optimal biomarker frequencies for multimarker biosensors has wide ranging uses from rapid cancer screening methodologies, dry diagnostics, providing personalized medicine and helping to detect comorbidities before they become a problem.

What is the current gold standard for the development of biomarkers? What are the limits of the current state of the art methods?

The current gold standard assays, besides optical methods like ELISA, include magnetic ones such as magnetic nanotags and beads, and Raman spectroscopy which has recently proved very popular.

These all provide different advantages in terms of detection limits or modalities but they all share limitations on labelling and complicated sample preparation. Raman spectroscopy is good as it can achieve label free detection but it’s still an expensive piece of equipment.

Ideally you want to achieve something similar to a blood glucose meter; easy to produce and very cheap. The test strips used to perform the test are less than one dollar per test strip, usually around five to ten cents.

None of these technologies have the capability to reach down to that scale yet, however electrochemical methods of biomarker detection are much closer to reaching this level than other technologies.

Please give a brief overview of your research that lead you to being named the Metrohm Young Chemist Award winner.

I work in a highly interdisciplinary lab with Dr. Jeffrey La Belle, comprising of three core- subject areas: biosensors, wearable technologies and advanced manufacturing. When I first joined I managed around eight different projects, and while I learned a lot, it wasn’t particularly focused.

Dr La Belle has trained me to think about how to utilize the common themes among these projects as stepping stones to help me wade across the river and achieve a larger goal.

We had a theory about the optimal frequency of a biomarker, which helps you achieve either a single biomarker detection or a multiple marker detection.

I started to grasp this idea and use these projects to develop single or multimarker sensors for certain diseases. I learned what the commonalities and differences are that constitute this optimal frequency and figured out how to exploit these to achieve a better, more sensitive multimarker sensing platform.

The award wasn’t just for the scientific novelty, but that we created applications that can be applied to all kinds of diseases with a focus on commercial ability. Many of our collaborators are industry partners and we design and develop their second-generation products. We also work with doctors to get their inputs during the design process.

How are the electrochemical biosensors produced and customized for complex diseases?

We typically start with a gold electrode to get an idea of how this antibody or this biomarker will behave. Once we get an idea of the reagents we’re working with, we transition toward screen printed electrodes, either gold or carbon.

Depending on the material, we then alter its surface chemistry to achieve good surface coverage and immobilization before trying to characterize and go through a series of designed experiments to find the optimal frequency of this biomarker, then we optimize the surface coating to ensure robustness against interfering species. Eventually we have our disposable test strips for this specific biomarker.

The multimarker part requires a lot more work, because our multimarker approach is actually not a sensor array. In a sensor array you have different working electrodes and each working electrode has a different molecular recognition element.

Our method involves immobilizing different analytes on the same working electrode. We focus on finding the optimal frequency of a specific biomarker, and once we find say two of them, we put both biomarkers on the same surface and monitor them just by looking at the optimal frequencies.

What is electrochemical impedance spectroscopy? How can it be used to create sensitive and rapid biosensors?

Electrochemical impedance spectroscopy (EIS) inputs a sinusoidal signal which consists of a very broad frequency range of one milli hertz to 100,000 hertz. Some of the machines can go up to one megahertz.

When these sinusoidal waves interact with the biomolecules, antibodies or antigens, we can measure the impedance change, the capacitance change and the frequencies.

There is a recognized concept of an optimal frequency, which represents the molecular frequency of interactions between the molecular recognition element and the protein of interest.

Once you find the optimal frequency, the impedance signals generated from that specific frequency can then be used to accurately detect the biomarker.

By finding that frequency there’s also an advantage in terms of shortening the assay time as you only need to search for a small frequency range, rather than the entire spectrum of one milli hertz to one megahertz. That would also drastically shorten the assay time.

How do electrochemical biosensors differ from traditional means of detecting biomarkers (i.e. ELISA)? How can they be used to for the diagnosis of complex diseases and comorbidities?

I would say the biggest difference would come from the labeling approach. The electrochemical impedance spectroscopy features a label free option, meaning you don’t have to mess with your sample.

You can produce your test strip, then just place the samples on the test strip and let it run, which is very different from ELISA in terms of simple preparation. Another difference is the cost of the meter. ELISA requires very bulky, sophisticated and expensive instruments, whereas the EIS is very capable of developing miniaturized meters, just like blood glucose meters.

We have been working on the EIS portable meters and we find that they are very easy to control, and it is easy to produce a meter cheaper than an iPhone. This, together with the low cost of under a dollar per test strip, will help to achieve personalized biomarker detection in healthcare.

What advantages are there to multimarker platforms of electrochemical biosensors over single biomarker monitoring? What effect will these multimarker platforms have on the evaluation of complex disease states?

Complex diseases often come with a lot of comorbidities, usually chronic diseases, that occur simultaneously. By the time we detect these chronic diseases it’s usually too late, so having a method for early diagnosis is very important.

One reason for the late detection, is that from a patient’s perspective, unless they have a medical emergency or symptoms that drive them to see a healthcare professional, they probably won’t spend hours in a hospital and wait weeks for test results.

If we have a multiplexed biosensor that is easy to administer, can be performed in a primary care setting and doesn’t take too long to produce results, we hope to increase screening rates and in that regard we could get a much more comprehensive view of the state of the disease than with a single marker.

We can enhance that with the rapid multimarker bio assays. In the future, patients may be able to visit their doctor’s office, have multimarker tests performed by a nurse and by the time they’re sitting with a doctor, the results would already be available. This would avoid lengthy hospital visits and contribute to a major increase in the efficiency of the healthcare.

What are the limitations of multimarker platforms using electrochemical biosensors?

Every biomarker is quite different. Some biomarkers are very highly concentrated in the body, some are very low, and some of the antibody antigen binding interactions take much longer, for example.

To design a specific biosensor to take into account all these factors is very time consuming. In theory it’s doable but in reality, every biomarker would involve a significant amount of work, so we will need sufficient resources to develop them.

What does the future hold for your research?

Right now, we are working with start-up companies to develop their second-generation products, for example, dry eye diagnostics and rapid cancer screening methodologies. Being able to see these go from development to reality is a very good achievement.

For example, with cancer if rapid screening can become available or at least a convenient means for people to test whenever or not they have these biomarkers, will provide people with reassurance and comfort while also catching these diseases early enough that treatment is effective.

Those are all the things that I’d really love to see come to fruition. Career-wise, I hope that this sensor platform can work towards personalized medicine, whether through start-up companies or using my expertise with big companies to further enhance their products.

Regardless of which route is taken, hopefully we can all converge towards personalized medicine through increasing efficiency of healthcare.

About Chi-En Lin

Chi-En is a Ph.D. candidate at Arizona State University where he works under the mentorship of Dr. Jeffrey T. La Belle, Assistant Professor at the School of Biological and Health Systems Engineering.

Chi-En Lin was the 2018 recipient of the Metrohm Young Chemist Award.

Tagged with:

About author

Related Articles